Study of Pimecrolimus Treatment for Atopic Dermatitis of African American Children

A 3-Week, Single-Blind, Placebo-Controlled, Within-Patient, Randomized Study of Pimecrolimus Treatment for Atopic Dermatitis of African American Children

Primecrolimus cream 1% is effective in the treatment of atopic dermatitis in African American children.

Inclusion Criteria:

• African American children aged 2 to 17 years
• mild to moderate atopic dermatitis

Exclusion Criteria:

• m-EASI less than 3 at baseline
• allergy to Elidel or components
• use of oral steroids, immunosuppressive agents,cytostatics of phototherapy within 4 weeks prior to study.
• previous continuous or non-continuous use of pimecrolimus or tacrolimus for greater than 11 months within 2 weeks of enrollment.
• active skin infections.
• immunocompromised patients.
• previous history of skin cancer or lymphoma
• any hypopigmentation in study areas
• pregnant or breastfeeding
• participation in another investigational trial